Autonomix Medical, Inc Common Stock

Yahoo Finance • 2 days ago

Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System 

GLP study marks a key milestone in Autonomix's path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo F... Full story

Yahoo Finance • 8 days ago

Autonomix Medical registers 2.5M shares for resale under $15M equity deal with Lincoln Park

* Autonomix Medical (NASDAQ:AMIX [https://seekingalpha.com/symbol/AMIX]) has filed a prospectus to allow resale of up to 2.5M shares of common stock by Lincoln Park Capital Fund. * Includes 2.24M purchase shares that may be issued to L... Full story

Yahoo Finance • 27 days ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced results from the post hoc analysis of its proof-of-concept human clinical trial (“PoC 1”) THE WOODLANDS, TX, Sept. 04, 2025 (GLOBE NEWSW... Full story

Yahoo Finance • 29 days ago

Curious about the stocks that are showing activity after the closing bell on Tuesday?

After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE... Full story

Yahoo Finance • 29 days ago

Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference

THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving th... Full story

Yahoo Finance • last month

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

Live video webcast on Thursday, August 21st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on adv... Full story

Yahoo Finance • 2 months ago

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

– Live video webcast on Thursday, August 21st at 2:20 PM ET THE WOODLANDS, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precis... Full story

Yahoo Finance • 2 months ago

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption (“IDE”), and if approved, the commencement of U.S. clini... Full story

Yahoo Finance • 2 months ago

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

– Video webcast now available on-demand THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to... Full story

Yahoo Finance • 2 months ago

Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds

THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has enter... Full story

Yahoo Finance • 2 months ago

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unloc... Full story

Yahoo Finance • 3 months ago

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO... Full story

Yahoo Finance • 3 months ago

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study

Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer... Full story

Yahoo Finance • 3 months ago

Autonomix receives US patent for nerve-sensing medical technology

THE WOODLANDS, TX - Autonomix Medical, Inc. (NASDAQ:AMIX), a medical technology company with a current market capitalization of $3.5 million and strong liquidity position evidenced by a current ratio of 5.63, has been granted U.S. Patent N... Full story

Yahoo Finance • 4 months ago

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain

Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strateg... Full story

Yahoo Finance • 5 months ago

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here Additional indications potentially double the addressable market beyond pancre... Full story

Yahoo Finance • 5 months ago

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain

Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here THE WOODLANDS, TX, May 05, 2025 (GLOB... Full story

Yahoo Finance • 5 months ago

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

THE WOODLANDS, TX, April 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving th... Full story

Yahoo Finance • 6 months ago

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WO... Full story

Yahoo Finance • 6 months ago

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a... Full story